Clinical trial
Erlotinib, Trastuzumab, and Paclitaxel in Treating Patients With Advanced Solid…
NCT00042809 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00042809 |
|---|---|
| Title | Erlotinib, Trastuzumab, and Paclitaxel in Treating Patients With Advanced Solid Tumors |
| Official title | Phase I Study To Determine The Safety, Tolerance And Preliminary Antineoplastic Activity Of Combined EGFR (erbB1) And HER2 (erbB2) Blockade, With OSI-774 And Trastuzumab, In Combination With Weekly Paclitaxel |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Biological, Drug, Other |
| Interventions | paclitaxel, trastuzumab, erlotinib hydrochloride, laboratory biomarker analysis, pharmacological study |
| Enrollment | 40 |
| Start date | May 1, 2002 |
| Primary completion | Dec 1, 2007 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 24, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: